Analyst
Canaccord Genuity
Equibles does not estimate personal net worth.
Edward Nash is recorded as Analyst at Canaccord Genuity. Edward Nash has spoken on 2 earnings calls and 7 other investor events across 8 companies, most recently for Kiniksa Pharmaceuticals International, plc on October 27, 2026. Those appearances were for Kiniksa Pharmaceuticals International, plc (KNSA), Rani Therapeutics Holdings, Inc. (RANI), Veru Inc. (VERU), Travere Therapeutics, Inc. (TVTX), Sagimet Biosciences Inc. (SGMT) and 3 other companies. The companies whose calls Edward Nash spoke on are classified in the Healthcare sector.
“I'm really, really excited to see that over $1 billion number now for the guidance, so congratulations. I just want to ask now, you're at 23% active penetration.”
“I have the pleasure of having Ronnie Therapeutics with us this afternoon. From Ronnie is Talat Imran, who is the company's CEO, and Nick Mestas, who is the company's Chief Financial Officer.”
“It is my pleasure to have with us today the management team from Connexia Pharmaceuticals. This is the name we currently cover with a buy rating. Joining us from the company is Ross Mote, the company's Chief Operating Officer, and John Paolini, the company's Chief Medical Officer.”
“I'm a senior biotech analyst here at Canaccord Genuity in the Equity Research Department. I have the pleasure of having Mitch Steiner with me today. He is the CEO of Viru.”
“It's my pleasure to have with us Trevier Therapeutics. From Trevier, joining us, we have Chris Klein, who is the company's Chief Financial Officer. Thanks very much for joining us today.”
Canaccord Genuity
Analyst
Transcript header (unverified)
Drug Manufacturers - Specialty & Generic · Healthcare
VERU
Biotechnology · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
